Grants & Awards

Print
PDF

Barts Haematologists Awarded International Research Mentorship Programme

on 17 April 2012.

TRTH-Logo

 

4def38ffb57a1

 

american-society-hematology


This year marks the third year of the prestigious Translational Research Training in Hematology (TRTH) programme, and the third year that the Centre for Haemato-Oncology at Barts Cancer Institute, Queen Mary, University of London has produced a successful candidate.

The TRTH program is a joint effort of the European Hematology Association (EHA) and the American Society of Hematology (ASH) and is focused on helping early-career scientists build successful careers in hematological translational research. Twenty scientists are selected through a competitive 2 stage process – an initial letter of intent with an abstract of their research followed by a full research proposal. The programme contains a week-long spring course and two follow-up meetings where trainees make a presentation on the status of their research.  The TRTH faculty is made up of international leaders in hematology who cover biostatistics and biomarkers, genetics and molecular biology, ethics, and phase I clinical study design.

Our prize-winners discuss their experiences below;

“I was lucky enough to be chosen to participate in the inaugural TRTH meeting in 2010. 20 junior haematology researchers from Europe and North America, we converged for a week in the company of some of the most highly respected senior clinician scientists and statisticians in this field. It was a humbling experience and an immense privilege to be able to work through my own research plans with world experts.”

Dr Simon Hallam


“The EHA-ASH TRTH award provides a fantastic opportunity for early career researchers from both sides of the Atlantic to come together and be mentored by some of the leading experts and statisticians in translational haematology. At the initial week-long meeting I was inspired by the work of my fellow researchers and excited to be able to get a peer review of my research in an informal small working group setting. It was also an excellent forum to exchange ideas with fellow researchers.”

Dr Sunil Iyengar


“I feel honoured to participate in the 2012 TRTH meeting. The spring course was an intense unique experience which I thoroughly enjoyed. It was very important for my work and my progression to have an excellent panel of peer reviewers exploring and criticizing my project. Meeting the faculty and another 19 inspired young researchers also motivated me to network and expand my research aims."

Rita Coutinho

For more information about EHA-ASH Translational Research Training in Hematology, click here.

Related Links:

Print
PDF

BCI and William Harvey Research Institute awarded grant to examine Stem Cells

on 22 February 2012.

Tysonbtlc


Dr Tyson Sharp (pictured) from the Barts Cancer Institute along with colleagues from the William Harvey Research Institute - Prof. Leo Dunkel, Prof. Andrew Tinker and Principal Investigator Dr Tristan McKay - at Queen Mary, University of London, have been jointly awarded a grant by Barts and the London Charity. The grant will be used to set up a new labratory examining induced Pluripotent Stem Cells (iPSc).

iPSc reprogramming allows scientists with the right tools and skills to turn a skin cell into a stem cell capable of faithfully differentiating into any cell-type in the human body. This effectively provides researchers with patient-derived liver, heart, lung, brain, etc. cells from a single skin biopsy.

A central iPSc reprogramming facility, situated in the William Harvey Research Institute, will be established to specifically generate iPSc cultures from patients seen in Bart’s clinics, in order to compare genetic changes with the effects seen in cells affected by cancer, endocrinological and cardiac disease.

This will provide a unique platform to relate genomic information with cellular behaviour in cell types specifically affected by disease, in individual living patients, and help to translate scientific observations into hospital treatments.


Related Links:

Print
PDF

Professor Nick Lemoine awarded Pancreatic Cancer Research Fund grant

on 06 February 2012.

NickPCRF


Researchers are hoping to uncover the factors that drive pancreatic cancer to develop and progress. One such factor may be the genes that are found in patients with the most aggressive form of the disease. If specific genes can be identified as being important for cancer growth, then the disease may be treated and managed more efficiently, improving the prognosis for patients.

Professor Nick Lemoine and his team have identified a specific gene that is found in the very aggressive form of pancreatic cancer, leading them to believe its presence is associated with a poorer prognosis.

In the PCRF-funded project, Professor Lemoine aims to study the effects of this gene in pancreatic cancer by recreating the disease in mice and hopes to discover information about how it is involved in the aggressive behaviour of the disease in patients. From this, he believes drugs may be developed that will be more effective at treating the cancer than those currently available.


Related Links: